Welcome to our dedicated page for Veradigm news (Ticker: MDRX), a resource for investors and traders seeking the latest updates and insights on Veradigm stock.
Veradigm Inc. reports developments tied to its healthcare data and technology business, including clinical and revenue cycle solutions for independent medical practices and data-driven offerings across provider, payer and biopharma markets. Company updates frequently reference the Veradigm Network, EHR-based analytics, real-world evidence, value-based care workflows, payer insights, coding services and revenue cycle management.
Recurring news also covers financial and business updates, financing activity, customer selections, product and content initiatives, leadership changes, stockholder rights-plan actions and the company’s reporting-status matters. These updates frame Veradigm as a healthcare technology issuer whose common stock trades under MDRX on the OTC market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Veradigm (NASDAQ: MDRX) announced that its solution, Practice Fusion, ranked first in Allergy and Immunology and second in Rheumatology in Black Book’s 2023 Ambulatory EHR by Physician Specialty category. Practice Fusion, designed for independent practices, supports over 31,000 clinicians and facilitates care for 5 million patients monthly. The EHR system enhances operational efficiency through features like clinical charting and e-prescribing. Tom Langan, President and CCO of Veradigm, emphasized the company’s commitment to empowering independent healthcare providers with cost-effective tools and cloud technology.
Veradigm Inc. (NASDAQ: MDRX) announced a delay in filing its Form 10-K due to expanded audit procedures necessitated by internal control deficiencies in revenue recognition. The cumulative revenue impact has escalated from an initial estimate of $20 million to approximately $40 million, which will require restating financial statements for 2021. Nasdaq has notified the company of non-compliance with timely filing requirements, but this has no immediate impact on stock trading. For fiscal 2023, revenue guidance has been revised downward to $615-$635 million, slightly reducing from the previous range. Non-GAAP earnings per share are forecasted to be between $0.80 and $0.90.
Summary not available.
Veradigm Inc. (NASDAQ: MDRX) announced internal control failures related to revenue recognition over the last six quarters due to errors in a software tool implemented for compliance with FASB’s ASC 606 rule. This has resulted in an estimated revenue misstatement of approximately $20 million, impacting reported Operating Income and Net Income, while cash flows remain unaffected. Consequently, the company has filed a Form 12b-25 with the SEC to extend its Form 10-K filing deadline by 15 days. Financial guidance for Fiscal 2023 has been revised, projecting revenue between $625 million and $645 million and Non-GAAP EPS between $0.80 and $0.90.
Veradigm Inc. (NASDAQ: MDRX) has appointed Susan Rodriguez and Shih-Yin Ho, MD, to its Board of Directors. Rodriguez brings over 30 years in the biopharmaceutical sector, currently serving as Chief Commercial Officer at Ardelyx, with prior leadership roles at Tolmar Pharmaceuticals and Abbott Laboratories. Dr. Ho, a digital health entrepreneur, has over 20 years of experience in health information and analytics, previously leading Aetion Inc. and co-founding Last Mile Research. Their expertise aims to enhance Veradigm's efforts in building the Veradigm Network, benefiting stakeholders significantly.
Veradigm, Inc. (NASDAQ: MDRX) will announce its financial results for the three and twelve months ending December 31, 2022, after market hours on March 1, 2023. The company plans to host a conference call at 4:30 p.m. ET to discuss these results. Participants can join via the Investor Relations website or by dialing 877-269-7756 for conference details.
A replay will be available for one year post-call. Veradigm specializes in healthcare technology, providing a network of data-driven solutions.